TERT启动子突变和膀胱癌临床病理特征关系的Meta分析
Association Between TERT Promoter Mutations and Clinicopathological Characteristics in Bladder Cancer: A Meta-Analysis
DOI: 10.12677/acm.2025.1551465, PDF,   
作者: 郭 瑞, 居红格, 马 强*:内蒙古科技大学包头医学院,内蒙古 包头
关键词: TERT膀胱癌Meta分析TERT Bladder Cancer Meta-Analysis
摘要: 目的:采用Meta分析评价TERT启动子突变和膀胱癌临床病理特征的关系。方法:检索Cochrane Library、Embase、PubMed、Web of Science、万方全文数据库、中国知网数据库,搜索与TERT启动子突变相关的膀胱癌的病例对照研究,检索截至2024年11月。两名研究人员独立筛选文献、提取信息、整理数据、评估纳入研究的偏倚风险,然后使用Review Manager 5.3进行汇总分析。结果:经数据库检索后,共检索到1575篇文献,排除综述论文、会议论文和无关研究等文献后,最终共纳入8篇文献,共1130例患者。Meta分析结果表明,TERT启动子突变与性别之间存在关联,男性患者比女性患者更易发生TERT启动子突变。结论:与女性膀胱癌患者相比,男性膀胱癌患者更容易出现TERT启动突变,这暗示了膀胱癌中存在与性别相关的潜在分子机制,为实验室和临床肿瘤研究提供了新的方向。
Abstract: Objective: To evaluate the relationship between TERT promoter mutations and clinical pathological features of bladder cancer using a Meta-analysis. Methods: We searched PubMed, the Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases for case-control studies on TERT promoter mutations in bladder cancer, with data up to November 2024. Two researchers independently screened the literature, extracted data, and assessed the risk of bias in the included studies. Meta-analysis was conducted using Review Manager 5.3. Results: A total of 1575 studies were identified through database searches. After excluding review articles, conference papers, and irrelevant studies, 8 studies with a total of 1130 patients were included. The Meta-analysis results showed that TERT promoter mutations are somewhat related to gender, with males being more likely to have TERT promoter mutations than females. Conclusion: Male bladder cancer patients are more likely to experience TERT promoter mutations compared to female bladder cancer patients. This suggests the presence of gender-related potential molecular mechanisms in bladder cancer, providing new insights for laboratory and clinical cancer research.
文章引用:郭瑞, 居红格, 马强. TERT启动子突变和膀胱癌临床病理特征关系的Meta分析[J]. 临床医学进展, 2025, 15(5): 1045-1054. https://doi.org/10.12677/acm.2025.1551465

参考文献

[1] Atala, A. (2015) Re: TERT Promoter Mutations and Telomerase Reactivation in Urothelial Cancer. Journal of Urology, 194, 848-849. [Google Scholar] [CrossRef] [PubMed]
[2] Stasik, S., Salomo, K., Heberling, U., Froehner, M., Sommer, U., Baretton, G.B., et al. (2019) Evaluation of TERT Promoter Mutations in Urinary Cell-Free DNA and Sediment DNA for Detection of Bladder Cancer. Clinical Biochemistry, 64, 60-63. [Google Scholar] [CrossRef] [PubMed]
[3] Zvereva, M., Pisarev, E., Hosen, I., Kisil, O., Matskeplishvili, S., Kubareva, E., et al. (2020) Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer. International Journal of Molecular Sciences, 21, Article 6034. [Google Scholar] [CrossRef] [PubMed]
[4] Yang, C., Hung, W., Wang, S., Kang, W., Chen, W., Huang, Y., et al. (2008) Immunoexpression and Prognostic Role of HTERT and Cyclin D1 in Urothelial Carcinoma. APMIS, 116, 309-316. [Google Scholar] [CrossRef] [PubMed]
[5] 谭卿. 尿路上皮肿瘤TERT启动子突变的研究[D]: [博士学位论文]. 北京: 北京协和医学院, 2016.
[6] 刘扬, 邢雪莎, 王贺意, 罗阳, 王侠. 膀胱癌中TERT启动子突变分析及其复发的意义[J]. 现代泌尿外科杂志, 2017, 22(3): 176-180.
[7] Descotes, F., Kara, N., Decaussin-Petrucci, M., Piaton, E., Geiguer, F., Rodriguez-Lafrasse, C., et al. (2017) Non-Invasive Prediction of Recurrence in Bladder Cancer by Detecting Somatic TERT Promoter Mutations in Urine. British Journal of Cancer, 117, 583-587. [Google Scholar] [CrossRef] [PubMed]
[8] Hosen, I., Rachakonda, P.S., Heidenreich, B., de Verdier, P.J., Ryk, C., Steineck, G., et al. (2015) Mutations in TERT Promoter and FGFR3 and Telomere Length in Bladder Cancer. International Journal of Cancer, 137, 1621-1629. [Google Scholar] [CrossRef] [PubMed]
[9] El Azzouzi, M., El Ahanidi, H., Hassan, I., Tetou, M., Ameur, A., Bensaid, M., et al. (2024) Comprehensive Behavioural Assessment of TERT in Bladder Cancer. Urologic Oncology: Seminars and Original Investigations, 42, 451.e19-451.e29. [Google Scholar] [CrossRef] [PubMed]
[10] Roggisch, J., Ecke, T. and Koch, S. (2020) Molecular Identification of Telomerase Reverse Transcriptase (TERT) Promotor Mutations in Primary and Recurrent Tumors of Invasive and Noninvasive Urothelial Bladder Cancer. Urologic Oncology: Seminars and Original Investigations, 38, 77.e17-77.e25. [Google Scholar] [CrossRef] [PubMed]
[11] Pérez González, S., Heredia-Soto, V., Girón de Francisco, M., Pérez-Fernández, E., Casans-Francés, R., Mendiola Sabio, M., et al. (2024) Telomerase Reverse Transcriptase-Promoter Mutation in Young Patients with Bladder Tumors. Current Issues in Molecular Biology, 46, 2845-2855. [Google Scholar] [CrossRef] [PubMed]
[12] Wang, K., Liu, T., Liu, C., Meng, Y., Yuan, X., Liu, L., et al. (2015) TERT Promoter Mutations and TERT mRNA but Not FGFR3 Mutations Are Urinary Biomarkers in Han Chinese Patients with Urothelial Bladder Cancer. The Oncologist, 20, 263-269. [Google Scholar] [CrossRef] [PubMed]
[13] Dong, M., Cioffi, G., Wang, J., Waite, K.A., Ostrom, Q.T., Kruchko, C., et al. (2020) Sex Differences in Cancer Incidence and Survival: A Pan-Cancer Analysis. Cancer Epidemiology, Biomarkers & Prevention, 29, 1389-1397. [Google Scholar] [CrossRef] [PubMed]
[14] 韩仁强, 郑荣寿, 张思维, 等. 1989年-2008年中国肺癌发病性别、城乡差异及平均年龄趋势分析[J]. 中国肺癌杂志, 2013, 16(9): 445-451.
[15] 贺宇彤, 郑荣寿, 孙喜斌, 等. 中国恶性肿瘤性别发病差异分析[J]. 中国肿瘤, 2013, 22(3): 174-179.
[16] 李辉章, 郑荣寿, 杜灵彬, 等. 中国膀胱癌流行现状与趋势分析. 中华肿瘤杂志, 2021, 43(3): 293-298.
[17] 张志凌, 周芳坚. 膀胱癌的诊断和治疗进展[J]. 临床外科杂志, 2015, 23(2): 91-92.
[18] Netto, G.J. (2011) Molecular Biomarkers in Urothelial Carcinoma of the Bladder: Are We There Yet? Nature Reviews Urology, 9, 41-51. [Google Scholar] [CrossRef] [PubMed]
[19] Cong, Y. (1999) The Human Telomerase Catalytic Subunit hTERT: Organization of the Gene and Characterization of the Promoter. Human Molecular Genetics, 8, 137-142. [Google Scholar] [CrossRef] [PubMed]
[20] Hafezi, F. and Perez Bercoff, D. (2020) The Solo Play of TERT Promoter Mutations. Cells, 9, Article 749. [Google Scholar] [CrossRef] [PubMed]
[21] Killela, P.J., Reitman, Z.J., Jiao, Y., et al. (2013) TERT Promoter Mutations Occur Frequently in Gliomas and a Subset of Tumors Derived from Cells with Low Rates of Self-Renewal. Proceedings of the National Academy of Sciences of the United States of America, 110, 6021-6026.
[22] El Zarif, T., Machaalani, M., Nawfal, R., Nassar, A.H., Xie, W., Choueiri, T.K., et al. (2023) TERT Promoter Mutations Frequency across Race, Sex, and Cancer Type. The Oncologist, 29, 8-14. [Google Scholar] [CrossRef] [PubMed]